Vibalogics Increases Capacity with New Manufacturing Line
Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing for its specialist oncolytic virus and viral vector manufacturing services as a result of a growth in demand.
Vibalogics, a contract development and manufacturing organization (CDMO), has increased its single-use bioreactor and purification capacity with a new manufacturing for its specialist oncolytic virus and viral vector manufacturing services as a result of a growth in demand.
The new manufacturing line, which features 50-L and 200-L single-use bioreactors as well as a Siemens process control system, will enable the company to enhance its position within the area of GMP-compliant manufacturing of complex biologicals. Additionally, as a complementary offering, the company has added an Äkta-ready chromatography system for downstream processing and liquid handling equipment, which will be used to deal with the higher volumes.
“As a leading specialist in the aseptic processing of live biological products, we continue to increase our capacity and scale of operations in line with the growing global demand for these services and already have orders in place for the 200-lit system up to the second half of 2020,” said Dr. Stefan Beyer, managing director at Vibalogics. “This additional processing capability ensures that we have the necessary infrastructure in place to handle larger batch volumes for our customers.”
Source: Vibalogics
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
